신테카바이오

226330KOSDAQ소프트웨어 개발 및 공급업

59.1 / 100

Reference Date: 2026-07-24

Financial Score14.5 / 40

News Sentiment21.6 / 25

Momentum8.0 / 20

Disclosure15.0 / 15

AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Declined 12.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Synetica Bio is a biotech venture company established in 2009, specializing in AI-driven drug discovery platforms and genomics big data solutions. Its core services include DeepMatcher® hit screening, personalized neoantigen identification (NEO-ARS®), and genomic precision medicine (NGS-ARS®), with revenue generated through both platform services and in-house drug pipelines. The company leverages its supercomputing infrastructure and partnerships to maintain a competitive edge in the industry.

Number of Employees

49people

Average Salary

61.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 12.284.0Point

PBR

1.08Industry Average 0.892.5Point

Higher than industry avg (caution)

ROE

-61.27Industry Average 1.100.0Point

Well below industry avg

Debt Ratio

7.90Industry Average 7.934.0Point

In line with industry avg

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲1367.3% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲4.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -41.1% (declining, 3yr)

Detailed News Sentiment

8 totalPositive 8Neutral 0Negative 0Average Sentiment Score 86.2

Positive
신테카바이오, 김동건 이사장 사내이사 추천…AI 진단 플랫폼 사업 확....
신테카바이오가 AI 진단 플랫폼 확장 전략을 발표하며 김동건 이사장의 사내이사 추천으로 새로운 성장 동력 확보에 긍정적 영향을 받고 있다.
Positive
신테카바이오, ADME·약동학 예측 고도화 "AI 기반 개량신약 자동설...
신테카바이오의 AI 기반 신약 개발 기술 고도화로 인해 혁신적인 개량신약 개발 가능성이 높아져 긍정적인 시장 반응 예상.
Positive
신테카바이오, 이젠의료재단과 AI 헬스케어 협업…"전략적 투자 연계.....
신테카바이오의 전략적 파트너십과 AI 헬스케어 분야 투자로 인해 기업 가치 상승 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,412Won52-week high 5,90052-week low 1,369

1-month return1.0Point

1m -12.73% (falling)

Volume trend6.0Point

Volume surge

Detailed Disclosure

16 totalPositive 3Neutral 13Negative 0

Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-07-23
Neutral주주총회소집결의 (임시주주총회)2026-07-20
Neutral주주명부폐쇄기간또는기준일설정2026-07-20
Neutral주식매수선택권부여에관한신고2026-07-20
Neutral주식등의대량보유상황보고서(일반)2026-07-15